Cancer biomarkers have transformed current practices in the oncology clinic. Continued
discovery and validation are crucial for improving early diagnosis, risk stratification, and …

Blood serum or plasma proteome is a gold mine of disease biomarkers. However,
complexity and a huge dynamic range of their components, combined with multiple …

In biological environments, nanomaterials associate with proteins forming a protein corona
(PC). The PC may alter the nanomaterial's pharmacokinetics and pharmacodynamics …

New biomarkers are urgently needed to accelerate efforts in developing new drugs and
treatments of known diseases. New clinical and translational proteomics studies emerge …

Mass spectrometry (MS)-based serum proteome analysis is extremely challenging due to its
high complexity and dynamic range of protein abundances. Developing high throughput and …

Antibody microarrays have the potential to enable comprehensive proteomic analysis of
small amounts of sample material. Here, protocols are presented for the production, quality …

Plasma is the most easily accessible source for biomarker discovery in clinical proteomics.
However, identifying potential biomarkers from plasma is a challenge given the large …

Mass spectrometry-based plasma proteomics is a field where intense research has been
performed during the last decade. Being closely linked to biomarker discovery, the field has …

This report used high-performance affinity microcolumns to examine the changes in binding
by sulfonylurea drugs to in vivo glycated HSA that had been isolated from individual patients …

Binding to plasma proteins highly influences drug efficacy, distribution, and disposition.
Serum albumin, the most abundant protein in plasma, is a monomeric multi-domain …